Peter Rahmer, See remarks at Relay Therapeutics, Inc. (RLAY), sold 161,818 shares at $4.15 ($691K) on 2025-01-02, disclosed to the SEC on 2025-01-06.
Scheduled sale ($691k) by See remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.15 | 32,156 | $133K | 19.3% |
| 2 | $4.15 | 32,156 | $133K | 19.3% |
| 3 | $4.30 | 32,177 | $138K | 20.0% |
| 4 | $4.30 | 32,177 | $138K | 20.0% |
| 5 | $4.45 | 16,576 | $74K | 10.7% |
| 6 | $4.45 | 16,576 |
| $74K |
| 10.7% |
| Total | $4.27 avg | 161,818 | $691K | 100% |
| Filing → |
| RLAY | SELL | 2026-07-02 | $955K | — | Filing → |
| RLAY | SELL | 2026-04-30 | $11K | — | Filing → |
| RLAY | SELL | 2026-01-29 | $100K | — | Filing → |